Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Breast 2Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 2Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glucose × Plasma cell × Clear all
NCT02253316 2025-11-10

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Washington University School of Medicine

Phase 2 Active not recruiting
236 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT03119883 2024-08-09

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

Mayo Clinic

Phase NA Completed
35 enrolled
Plasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡